Article Per Year (5 Year)
p-Index From 2020 - 2025
0.61
P-Index
This Author published in this journals
All Journal Journal of Biomedicine and Translational Research Narra J
Sutanto, Yusup S.
Unknown Affiliation
Biochemistry, Genetics & Molecular Biology Health Professions Immunology & microbiology Medicine & Pharmacology Public Health

Published : 3 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 3 Documents
Search

 1 
Neutrophil–Lymphocyte and Platelet–Lymphocyte Ratios are Predictors of Lung Malignancy Sutanto, Yusup S.; Rudiannor, Muhammad; Aphridasari, Jatu; Kurniawan, Hendra
Journal of Biomedicine and Translational Research Vol 10, No 2 (2024): August 2024
Publisher : Faculty of Medicine, Universitas Diponegoro

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.14710/jbtr.v10i2.20330

Abstract

Background: Inflammatory cells play an essential role in the neoplastic process by stimulating cancer proliferation, survival, and migration. Neutrophil-lymphocyte and platelet-lymphocyte levels can be used as the inflammatory tissue damage markers in cancer patients.Objective: This study aimed to analyze the increase of neutrophil-lymphocyte ratio (NLR) and platelet–lymphocyte ratio (PLR) as the predictive factors for lung malignancy.Methods: This study was a diagnostic cross-sectional study design in lung tumor patients at Dr. Moewardi Hospital Surakarta from August to October 2018. The subjects (60) were selected with consecutive sampling who take lung cancer diagnostic tests and divided into two groups of patients with lung tumors (30) and healthy (30) as control. The diagnostic procedures and neutrophil–lymphocyte and platelet–lymphocyte ratios calculation were performed on both groups. The optimum cutoff values for the NLR and PLR were calculated from the receiver operating curve analysis.Results: The statistical test found a significant difference in the neutrophil–lymphocyte and platelet–lymphocyte ratios between cancer patients and control (p = 0.0000). The lung cancer group exhibited an increase in the NLR with 90.0% sensitivity and 96.7% specificity with a cutoff of 2.71. The platelet–lymphocyte ratio had a cutoff of 136.63 at 83.3% sensitivity and 80.0% specificity.Conclusion: The increase of neutrophil-lymphocyte and the platelet-lymphocyte ratio can be used as a predictive predictor of lung malignancy.
Effectiveness of Zingiber officinale to reduce inflammation markers and the length of stay of patients with community-acquired pneumonia: An open-label clinical trial Reviono, Reviono; Hapsari, Brigitta DA.; Sutanto, Yusup S.; Adhiputri, Artrien; Harsini, Harsini; Suryawati, Betty; Marwoto, Marwoto; Syaikhu, Akhmad
Narra J Vol. 3 No. 1 (2023): April 2023
Publisher : Narra Sains Indonesia

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.52225/narra.v3i1.142

Abstract

Examination of the interleukin 6 (IL-6) and procalcitonin levels, and neutrophil-lymphocyte ratio (NLR) might could help to diagnosis and predict the duration of therapy and prognosis of pneumonia cases. Zingiber officinale var rubrum could be used as an adjunct therapy in infectious diseases as it has anti-inflammatory activity. The aim of study was to assess the effect of Z. officinale on levels of IL-6 dan procalcitonin, NLR, and the length of hospitalization of patients with community-acquired pneumonia (CAP). An open-label clinical trial was conducted among CAP cases regardless of the etiology at Dr Moewardi Hospital and Universitas Sebelas Maret Hospital, Surakarta, Indonesia from July to September 2022. A total of 30 inpatient CAP cases were recruited and were randomly divided into two groups: (1) received Z. officinale capsule 300 mg daily for five days in addition to CAP standard therapy; and (2) received CAP standard therapy only, as control group. The data were compared using a paired Student t-test, Chi-squared test, Mann-Whitney test and Wilcoxon signed-rank test as appropriate. In Z. officinale group, the mean difference between post- and pre-treatment as follow: IL-6 level was 9.93 pg/mL, procalcitonin level -471.31 ng/mL, and NLR value -4.01. In control group, the difference was 18.94 pg/mL for IL-6, 339.39 ng/mL for procalcitonin, and 1.56 for NLR. The change of IL-6 was not statistically significant between treatment and control groups with p=0.917. The changes of procalcitonin level and NLR were significant between treatment and control group with p=0.024 and p=0.007, respectively, of which the treatment had better improvement. In addition, our data indicated that the length of stay was not statistically significant between the treatment and control groups (4.13 vs 4.47 days, p=0.361). In conclusion, Z. officinale could reduce serum inflammatory markers such as procalcitonin and NLR but it has little impact in reducing IL-16 level and the length of hospitalization of CAP patients.
Effects of secretome supplementation on interleukin-6, tumor necrosis factor-α, procalcitonin, and the length of stay in acute exacerbation COPD patients Fahlevie, Fahlevie; Apriningsih, Hendrastutik; Sutanto, Yusup S.; Reviono, Reviono; Adhiputri, Artrien; Aphridasari, Jatu; Prasetyo, Windu
Narra J Vol. 3 No. 2 (2023): August 2023
Publisher : Narra Sains Indonesia

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.52225/narra.v3i2.171

Abstract

Acute exacerbation chronic obstructive pulmonary disease (AECOPD) is associated with significant poor survival. Mesenchymal stem cells (MSC) therapy has been a promising treatment for COPD; therefore, it has the potential to be an additional therapy for AECOPD. Its potential is associated with its secretome since it has anti-inflammatory and immunomodulator activities. The aim of this study was to determine the effect of the secretome as an adjuvant therapy in reducing the levels of interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), procalcitonin, and the length of stay in AECOPD patients. A clinical control trial study was conducted among 28 moderate and severe AECOPD patients who were hospitalized from January to February 2023. The control group (n=14) received standard therapy of AECOPD while the treatment group (n=14) received standard therapy plus secretome 1 ml twice daily for three days. The levels of IL-6, TNF-α, and procalcitonin were measured at admission and on the fourth day of treatment. The length of stay was calculated from the time the patient was admitted until the patient was discharged from hospital. The data were compared using a paired Student t-test, chi-squared test and Mann-Whitney test as appropriate. In the treatment group, the levels of IL-6, TNF-α and procalcitonin after the treatment reduced 13.09 pg/mL, 5.00 pg/mL and 751.26 pg/mL, respectively compared to pre-treatment. In contrast, the levels of IL-6, TNF-α and procalcitonin increased 48.56 pg/mL, 44.48 pg/mL and 346.96 pg/mL, respectively after four days of treatment. There was a significant reduction of IL-6, TNF-α and procalcitonin in treatment group compared to the control group with p=0.022, p=0.009 and p=0.001, respectively. However, there was no significant reduction of the length of stay (p=0.072). In conclusion, administration of secretome to AECOPD patients could reduce the levels of IL-6, TNF-α and procalcitonin.
Co-Authors AA Sudharmawan, AA Adhiputri, Artrien Akhmad Syaikhu Apriningsih, Hendrastutik Fahlevie, Fahlevie Hapsari, Brigitta DA. Jatu Aphridasari marwoto marwoto Mochammad Imron Awalludin Reviono Reviono Rudiannor, Muhammad SURYAWATI, BETTY Windu Prasetyo, Windu